Why does Gilead expect a loss in 2026?

Due to expenses from acquiring research and development assets, resulting in an adjusted loss per share of $1.05 to $0.65.

What is the expected adjusted loss per share range?

Between $1.05 and $0.65 per share.

How did Gilead's guidance change from previous expectations?

Previous guidance was for adjusted earnings of $8.45 to $8.85 per share; now it expects a loss.

Will this guidance affect Gilead's stock?

It is expected to pressure the stock negatively in the near term due to the negative surprise.

Gilead Expects 2026 Adjusted Loss on R&D Acquisition Costs

Gilead Sciences announced it expects an adjusted loss per share of $1.05 to $0.65 for 2026, compared to prior guidance of adjusted earnings of $8.45 to $8.85 per share, due to expenses from acquired research and development assets.

Gilead Sciences (GILD) announced it expects an adjusted loss per share for 2026 in the range of $1.05 to $0.65, a sharp reversal from its previous guidance of adjusted earnings between $8.45 and $8.85 per share. The significant downgrade is primarily attributed to expenses related to acquired research and development assets.

Key Financial Results

Metric	Value
2026 Adjusted Loss Per Share Range	$1.05 - $0.65
Previous 2026 Adjusted EPS Guidance	$8.45 - $8.85

Key Takeaways from the Announcement

Gilead attributed the substantial guidance revision to costs associated with acquiring R&D assets, which are expected to negatively impact adjusted earnings for the full year. The company did not provide further details on the nature or value of these acquisitions.

Future Guidance

Gilead now projects an adjusted loss of $1.05 to $0.65 per share, a stark contrast to its earlier profit forecast. This implies that acquisition expenses will significantly outweigh operating earnings.

Impact on the Stock

The announcement is likely to pressure Gilead's stock (GILD) in upcoming trading sessions, as the loss guidance represents a negative surprise for investors who had anticipated continued profitability.

What This Means for Investors

Investors should monitor details of Gilead's acquisitions, as these expenses could strengthen the product pipeline in the long term but negatively impact near-term profitability. It is advisable to watch upcoming reports to assess the potential return on these investments.